Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical leader focused on pioneering therapies for immuno-inflammatory and dermatologic diseases. This page serves as the definitive source for verified news and press releases related to ACRS's research advancements, strategic partnerships, and operational developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and financial announcements. The curated collection includes updates on novel drug candidates like kinase inhibitors and antibody therapies targeting conditions with significant unmet medical needs.
All content is organized to provide clear insights into ACRS's dual-segment operations – from therapeutic innovations to contract research services. Regular updates ensure stakeholders stay informed about licensing agreements, pipeline expansions, and scientific breakthroughs without promotional bias.
Bookmark this page for streamlined access to essential Aclaris Therapeutics updates. Check back frequently for authoritative reporting on developments impacting both clinical research and investment considerations in the biopharmaceutical sector.
Aclaris Therapeutics (NASDAQ: ACRS) has secured a $80 million private placement through the sale of 35,555,555 shares of common stock at $2.25 per share. The placement was led by Vivo Capital, with participation from both new and existing investors including Forge Life Science Partners, Rock Springs Capital, and RA Capital Management, among others. The transaction is expected to close around November 19, 2024. The proceeds will be used to fund research and development of the company's pipeline and general corporate purposes. The company has agreed to file a registration statement with the SEC for the resale of the shares.
Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 2024 financial results with a net loss of $7.6 million, improved from $29.3 million in Q3 2023. Revenue decreased to $4.3 million from $9.3 million year-over-year. The company maintains a strong cash position of $173.4 million, expected to fund operations into 2028.
Key developments include the first patient dosed in the ATI-2138 Phase 2a trial for atopic dermatitis, with top-line data expected in H1 2025. R&D expenses decreased to $6.0 million from $23.9 million, while G&A expenses reduced to $5.7 million from $7.1 million in the prior year period.
Aclaris Therapeutics (NASDAQ: ACRS) has announced the dosing of the first patient in its Phase 2a clinical trial of ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, for treating moderate to severe atopic dermatitis. The open-label study aims to evaluate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 over a 12-week period.
The trial plans to enroll approximately 15 subjects in the United States, with primary endpoints focusing on safety-related parameters. Secondary endpoints include EASI response measures, vIGA response, and BSA response. Aclaris expects to release topline data from this trial in the first half of 2025.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management team will engage in a fireside chat on Tuesday, September 17, 2024, at 8:00 AM ET in New York.
Investors and interested parties can access a webcast of the fireside chat through the 'Events' page in the 'Investors' section of Aclaris' website, www.aclaristx.com. The webcast will remain archived on the company's website for a minimum of 30 days, allowing for later viewing.
Aclaris Therapeutics (NASDAQ: ACRS) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Initiation of Phase 2a study activities for ATI-2138 in atopic dermatitis.
2. Strengthened balance sheet through sale of future OLUMIANT® royalties for up to $31.5 million.
3. Q2 2024 net loss of $11.0 million, compared to $29.6 million in Q2 2023.
4. Total revenue increased to $2.8 million in Q2 2024 from $1.9 million in Q2 2023.
5. R&D expenses decreased to $8.8 million from $25.3 million year-over-year.
6. Cash, cash equivalents, and marketable securities of $149.9 million as of June 30, 2024.
The company expects its current cash position, including the $26.5 million from the OLUMIANT® royalty sale, to fund operations into 2028.
Aclaris Therapeutics (NASDAQ: ACRS) has announced the sale of a portion of its future royalty payments and certain milestones for OLUMIANT® (baricitinib) to OMERS Life Sciences for up to $31.5 million. The deal includes a $26.5 million upfront payment and up to $5.0 million in potential milestone payments based on OLUMIANT sales in 2024. This non-dilutive transaction strengthens Aclaris' balance sheet, providing financial flexibility to pursue value-creating opportunities and invest in internal programs. OMERS acquires a portion of the royalty for worldwide net sales of OLUMIANT for alopecia areata from April 1, 2024, through the remainder of the royalty term, as well as 100% of the remaining anniversary milestone payments from Eli Lilly.
Aclaris Therapeutics (NASDAQ: ACRS) announced that Dr. Neal Walker, Interim President & CEO, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The event will take place on June 11, 2024, at 11:20 AM ET in Miami, Florida.
The chat will be webcasted and accessible via the company's website, where it will be archived for at least 30 days.
Aclaris Therapeutics reported its financial results for the first quarter of 2024 and provided a corporate update. The company is progressing ATI-2138 into a Phase 2a trial for atopic dermatitis. Aclaris also announced positive results for its various ITK inhibitor programs and highlighted financial data showing a decrease in net loss and revenue. The company anticipates lower cash expenditures in future quarters due to ongoing strategic reviews.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will announce its first quarter 2024 financial results on May 7, 2024. The company focuses on developing drug candidates for immuno-inflammatory diseases. A conference call will follow to provide a corporate update.
